APOPTOTIC PROTEINS AND CANCER: MANY FACES

Authors

  • Faris Q Alenzi
  • Mohamed L. Salem
  • Fadel S. Alyaqoub
  • Fahad G. B. Alanazi
  • Wafa G. Alanazi
  • Mona G. Alanazi
  • Abdulmajeed G. Alanazi
  • Majed G. Alanazi
  • Hamdan Al- Shehri
  • Abdulwahab A Abuderman
  • Waleed Tamimi

Abstract

Complex genetic and epigenetic alterations that disruptthe physiological regulation of apoptosis are thought tobe strategically critical for the carcinogenic process andare thought to provide survival and growth advantagesfor cancerous cells. Targeting and the induction ofapoptosis (programmed cell death) is an attractive targetfor successful cytotoxic therapy for many different typesof cancer, including leukaemias and lymphomas.1,2Bcl-2 proteinIn normal liver cells, Bcl-2 family members haveessential roles in liver homeostasis. On other hand, incarcinogenesis, these proteins play a significant role bysuppressing apoptotic death rather than stimulating cellproliferation. The up-regulation of either Bcl-2 or BclxL in mouse liver has been shown to protect hepatocytesfrom Fas-induced apoptosis and, therefore, liverdestruction in a dose-dependent manner.3 Recent datafrom our work demonstrated the protein expression ofcytoplasmic Bcl-2 in 16% of chronic HCV patients withno hepatocellular carcinoma (HCC) versus 8% inpatients with HCC.4 In HCC, Bcl-2 is significantlydown-regulated while Bcl-xL is predominatelyexpressed.5 However, Fiorentino et al reportedconsistent increased level of Bcl-2 RNA in HCC whichmay be suggest a post-transcription down-regulation ofBcl-2 at the protein level.5Another interesting finding was the delay ofliver tumour development in concordance with Bcl-2up-regulation in TGFα/Bcl-2 double transgenic mice6which appears to inhibit c-myc-induced livercarcinogenesis7. However, the in vivo electrophoretictransfer of Bcl-2 antisense oligonucleotide (ASO) intoliver demonstrated inhibitory effects on HCC in ratmodels.8 The deferential expression of Bcl-2 with theregards to tumours development could be contributed tothe expression status of p53. The expression of Bcl-2 issignificantly up-regulated in p53-positive HCC tissuewhile down-regulated in p53-negative tissues.9Changes in p53 and Bcl-2 protein expressionare a molecular hallmarks during hepatocarcinogenesis10that occur in concordance with high expression of theproliferating cell nuclear antigen (PCNA) and loss ofdifferentiation and HCC progression.11 The PCNAexpression is significantly elevated in late G1 and Sphases of proliferating cells, and has been used as abiomarker for progression in different types of cancersincluding HCC.12 The PCNA over-expression was evenconsidered as an indicator for increased risk of HCCdevelopment in HCV-infected patients.13,14Additionally, it was demonstrated that the celldivision rate and subsequently the size of thymocytespopulation in vivo is significantly reduced by theexpression of Bcl-2 or Bcl-xL in some reports15 whilethese two proteins can also inhibit apoptosis of dividingcells16. Bradly et al demonstrated that over-expressionof Bax and Bcl-2 in T-cell of transgenic mice can resultin disturbing the cell cycle of dividing thymocytes. Itwas found that while Bax has stimulatory effects, Bcl-2has inhibitory effects on cell cycle of cyclingthymocytes. Furthermore, in activated T-cells, Bcl-2overxpression was seen to delay the protein degradationof the tumour suppressor gene p27, whereas Baxaccelerated that.17Haemopoitic stem cells (HSC) with overexpressed Bcl-2 in Bcl-2-transgenic mice generated byDemon et al were reported to remain viable after growthfactor withdrawal whereas HSC from WT mice did notsurvive in the absence of growth factor. It wasdemonstrated that HSC from Bcl-2-transgenic miceresponded to pro-growth factors (such as IL-1, IL-3, IL-6, SCF and Flt3-ligand) with significantly faster andmore extensive proliferation with more delay in the cellcycle entry when compared with that from WT mice.Interestingly, when cultured with SCF, only 20% of WTHSC remained viable after one week, while HSC fromBcl-2-transgenic mice demonstrated greater survivalcapabilities and more extensive proliferation. It wasconcluded that over-expression of Bcl-2 and SCF/c-kitsignalling pathway are sufficient for HSC proliferation.However, one should note that proliferation alsoparticipated into the transformation of progenitor cells tothe myeloid lineage.18,19P53, Fas and Apaf-1A study by our group pointed out that in blast crisis(BC) of chronic myeloid leukaemia (CML) the p53expression is significantly increased when comparedwith the chronic phase of CML.20 Interestingly, whilerelatively high p53 expression was in general detectedJ Ayub Med Coll Abbottabad 2012;24(1)112 http://www.ayubmed.edu.pk/JAMC/24-1/Faris.pdfalong with up-regulation of apoptosis activating factor(Apaf-1), a significant down-regulation of Apaf-1 wasoddly seen when p53 had become clearly over-expressedsuggesting a disturbance in the p53 pathway (11, CMLpaper). Data from our group suggested decreasedexpression level of p53 and Apaf-1 in patients withBC.21 It seems that the Apaf-1 up-regulation by severaloncoproteins such as E2F1 is mechanistically critical forfacilitating the apoptosome assembly. Furthermore,Kannan et al demonstrated the presence of pointmutation, deletions and other genomic rearrangementsof p53 gene in 25% of BC and that p53 is an upstreamregulator of Apaf-1.22 In fact, we previously suggested alink between increased expression of p53, decreasedexpression of Apaf-1 and lack of Fas expression in onehand and progression of CML. Therefore, one should becareful towards understanding the significant upregulation of these pro-apoptotic genes in BCtransformation as well as in response to therapeuticapproaches.For any normally growing cell populationmolecular defects either at gene level, mRNA level orprotein level for genes regulating proliferation andapoptosis during cell cycle can interfere with thebalance between cell division and apoptosis for thatcellular population in vivo and provide strategicallyadvantageous scenario for carcinogenesis.23 Ourprevious results indicates that apoptosis (via Fas-FasL)play a role in regulating haemopoietic progenitor cellkinetics in humans as it does in mice. It also showed thatcaspases activation was required for the myeloidmaturation.24,25Cell cycle proteinsGenes regulating apoptosis have significant impact onthe cell cycle. A number of studies demonstrated thatcell-cycle regulators could interconnect withproliferation and apoptosis.Both p16–/– and p21–/– mice are deficient in keycell cycle genes, while lpr and gld mice (Fas and FasLmutant mice, respectively) have a defective apoptoticmechanism.24 However, Lewis et al26 showed that p16–/–knockout mice have a higher self-replication capacitythan do wild-type (WT) mice, which links the cell cycleand apoptosis. Similarly, p21–/– knockout mice have ahigher self-replication capacity (i.e., cell proliferation)than do WT mice.We showed that both lpr and gld mice have ahigher self-replication (i.e., cell proliferation) capacitythan do WT mice, which links apoptosis andproliferation.24 Miyashita et al27 showed that therestoration of p53 function resulted in down-regulationof Bcl-2 levels and the occurrence of apoptosis. Theyalso showed that p53 activates the Bax promoter andinduces high levels of Bax mRNA and protein.Moreover, Yin et al28 showed that Bax is required for50% of p53-induced apoptosis. Gomez et al29demonstrated a relationship between p27, cdk2 andapoptosis in thymocytes, which was modulated by p53,Bcl-2 and Bax. Thus, cdk2 activation seems to be thekey point at which the cell cycle and apoptosis meet.Janicke et al30 showed that the retinoblastoma(RB) gene is cleaved during apoptosis, at the caspaseconsensus cleavage site (DEAD), resulting in a proteinproduct of 50 kDa. Dou et al31 showed that RB is alsocleaved on an interior site, producing proteins of 48 and68 kDa. Fattman et al32 demonstrated that caspase-3 andcaspase-7 cleave RB at the DSID cleavage site, resultingin proteins of 68 and 48 kDa.These findings support a two-step model forRB cleavage and a promoting role in chemotherapymediated apoptosis. Browne et al33 demonstrated thatRB is cleaved at the carboxyl terminal, producing 43-and 30-kDa protein fragments. In addition, ZVAD wasfound to inhibit the cleavage of RB, poly-ADP-ribosepolymerase (PARP) and apoptosis. In contrast, YVADdid not inhibit primary carboxyl terminal cleavage ofRB and PARP. These results suggest that differentcaspases are responsible for the cleavage of differentsubstrates during apoptosis.In contrast, Suzuki and colleagues34demonstrated that survivin interacts with cdk4, and, as aresult, p21 is released from its complex with cdk4 andinteracts with pro-caspase-3 in mitochondria, resultingin inhibition of apoptosis. Cell-cycle transitions aremediated through multiple phosphorylations of cyclincdk complexes. RB phosphorylation releases E2Ftranscription factor, which activates certain genes duringS phase. Activation of p21 results in negative regulationof the cell cycle. P21 interacts with cdk and PCNA,

References

Alenzi FQ. Apoptosis and Diseases; Regulation and Clinical

Relevance (REVIEW). Saudi Med J 2005;26:1679–90.

Alenzi FQ. Links between apoptosis, cell cycle and proliferation

(REVIEW). Br J Biomed Sci 2004;61(2):99–102.

Rodriguez I, Matsuura K, Khatib K, Reed JC, Nagata S, Vassalli

P. A bcl-2 transgene expressed in hepatocytes protects mice from

fulminant liver destruction but not from rapid death induced by

anti-Fas antibody injection. J Exp Med 1996;183:1031–6.

Alenzi FQ, El-Nashar EM, Al-Ghamdi SS, Abbas MY, Hamad

AM, El-Saeed OM, et al. Investigation of Bcl-2 and PCNA in

Hepatocellular Carcinoma: Relation to Chronic HCV. J Egypt

Natl Canc Inst 2010;22(1):87–94.

Fiorentino M, D’Errico A, Altimari A, Barozzi C, Grigioni WF.

High levels of BCL-2 messenger RNA detected by in situ

J Ayub Med Coll Abbottabad 2012;24(1)

http://www.ayubmed.edu.pk/JAMC/24-1/Faris.pdf

hybridization in human hepatocellular and cholangiocellular

carcinomas. Diagn Mol Pathol 1999;8:189–94.

Vail ME, Pierce RH, Fausto N. Bcl-2 delays and alters hepatic

carcinogenesis induced by transforming growth factor alpha.

Cancer Res 2001;61:594–601.

de La Coste A, Mignon A, Fabre M, Gilbert E, Porteu A, Van

Dyke T, et al. Paradoxical inhibition of c-myc-induced

carcinogenesis by Bcl-2 in transgenic mice. Cancer Res

;59:5017–22.

Baba M, Iishi H, Tatsuta M. In vivo electroporetic transfer of bcl-

antisense oligonucleotide inhibits the development of

hepatocellular carcinoma in rats. Int J Cancer 2000;85:260–6.

Chiu CT, Yeh TS, Hsu JC, Chen MF. Expression of Bcl-2 family

modulated through p53-dependent pathway in human

hepatocellular carcinoma. Dig Dis Sci 2003;48:670–6.

Hussein MR. Alterations of p53, Bcl-2, and hMSH2 protein

expression in the cirrhotic, macro regenerative, dysplastic

nodules and hepatocellular carcinomas in Upper Egypt. Liver Int

;24:552–60.

Hu TH, Wang CC, Huang CC, Chen CL, Hung CH, Chen CH, et

al. Down-regulation of tumor suppressor gene PTEN,

overexpression of p53, plus high proliferating cell nuclear antigen

index predict poor patient outcome of hepatocellular carcinoma

after resection. Oncol Rep 2007;18:1417–26.

Akyol P, Mittal S, Protić M, Oryhon J, Korolev SV, Joachimiak

A, et al. Proliferating cell nuclear antigen (PCNA): ringmaster of

the genome. Int J Radiat Biol 2001;77:1007–21.

Dutta O, Ariza A, Llatjos M, Castella E, Mate JL, Navas-Palacios

JJ. Proliferating cell nuclear antigen expression in normal,

regenerative and neoplastic liver: A fine needle aspiration

cytology and biopsy study. Hum Pathol 1993;24:905–8.

Ballardini G, Groff P, Zoli M, Bianchi G, Giostra F, Francesconi

R, et al. Increased risk of hepatocellular carcinoma development

in patients with cirrhosis and with high hepatocellular

proliferation. J Hepatol 1994;20:218–22.

O'Reilly LA, Huang DC, Strasser A. The cell death inhibitor Bcl-

and its homologues influence control of cell cycle entry.

EMBO J 1996;15:6979.

Strasser A, Harris AW, Jacks T, Cory S. DNA damage can

induce apoptosis in proliferating lymphoid cells via p53-

independent mechanisms inhibitable by Bcl-2 Cell 1994;79:189.

Brady HJ, Gil Gomez G, Kirberg J, Berns AJ. Bax alpha perturbs

T cell development and affects cell cycle entry of T cells. EMBO

J 1996;15:6991.

Domen J, Weissman IL. Hematopoietic stem cells need two

signals to prevent apoptosis; BCL-2 can provide one of these,

Kitl/c-Kit signaling the other. J Exp Med 2000;192:1707.

Domen J, Cheshier SH, Weissman IL. The role of apoptosis in

the regulation of hematopoietic stem cells: Overexpression of

Bcl-2 increases both their number and repopulation potential. J

Exp Med 2000;191:253.

Bi S, Lanza F, Goldman JM. The abnormal p53 proteins

expressed in CML cell lines are non-functional. Leukaemia.

;7(11):1840–5.

Alenzi FQ, Wyse RK, Tamimi WG, Bamaga MS, Lotfy M. A

close link between Fas, p53 and Apaf-1 in chronic myeloid

leukemia. Saudi Med J 2007;28(7):1119–21.

Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio

N, Givol D. DNA microarray analysis of genes involved in p53

mediated apoptosis: activation of Apaf-1. Oncogene

:20:3449–55.

Feinstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi K

et al. p53 in chronic myelogenous leukemia in acute phase. Proc

Natl Acad Sci USA 1991:88:6293–7.

Alenzi FQ, Marley S, Chandrashekran A, Botto M, Warrens A,

Goldman J. Regulation of haemopoietic progenitor cell number

by the Fas/FasL apoptotic mechanism Exp Hematol

;30(12):1428–35.

Alenzi FQ, Al-Ghamdi SM, Tamimi WG, Al-Sebiany AM, ElNashar IM, El-Tounsi I, et al. Apoptosis role of FAS/FAS ligand

system in the regulation of myelopoiesis. Yale J Biol Med

;78(1):25–36.

Lewis JL, Chinswangwatanakul W, Zheng B, Marley SB,

Nguyen DX, Cross NC, et al. The influence of INK4 proteins on

growth and self-renewal kinetics of hematopoietic progenitor

cells. Blood 2001;97:2604.

Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK,

Liebermann DA, et al. Tumor suppressor p53 is a regulator of

bcl-2 and bax Oncogene 1994;9:1799.

Yin C, Knudson CM, Korsmeyer SJ, van Dyke T. Bax

suppresses tumorigenesis and stimulates apoptosis in vivo.

Nature 1997;385:637–40.

Gil Gomez G, Berns A, Brady HJ. A link between cell cycle and

cell death: Bax and Bcl-2 modulate Cdk2 activation during

thymocyte apoptosis. EMBO J 1998;17(24):7209–18.

Janicke RU, Walker PA, Lin XY, Porter AG. Specific cleavage

of the retinoblastoma protein by an ICE-like protease in

apoptosis. EMBO J 1996;15(24):6969–78.

Dou QP. Putative roles of retinoblastoma protein in apoptosis.

Apoptosis 1997;2(1):5–18.

Fattman CL, Delach SM, Dou QP, Johnson DE. Sequential Twostep cleavage of the retinoblastoma protein by caspase-3/-7

during etoposide-induced apoptosis. Oncogene

;20(23):2918–26.

Browne SJ, MacFarlan M, Cohen GM, Paraskeva C. The

adenomatous polyposis coli protein and retinoblastoma protein

are cleaved early in apoptosis and are potential substrates for

caspases. Cell Death Differ 1998;5(3):206–13.

Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi

Y, et al. Survivin initiates procaspase 3/p21 complex formation

as a result of interaction with Cdk4 to resist Fas-mediated cell

death. Oncogene 2000;19:1346–53.

Debatin KM, Goldman CK, Waldmann TA, Krammer PH. APO-

-induced apoptosis of leukemia cells from patients with adult Tcell leukaemia. Blood 1993;81:2972–7.

Westendorf JJ, Lammert LM, Jelinek DF. Expression and

function of Fas (APO-1/CD95) in patient myeloma cells and

myeloma cell lines. Blood 1995;85:3566.

Panayiotidis P, Ganeshaguru K, Foroni L, Hoffbrand AV.

Expression and function of the FAS antigen in B chronic

lymphocytic leukemia and hairy cell leukemia. Leukemia

;9:1227–32.

Komada Y, Zhou YW, Zhang XL, Xue HL, Sakai H, Tanaka S,

et al Fas receptor (CD95)-mediated apoptosis is induced in

leukemic cells entering G1B compartment of the cell cycle.

Blood 1995;86:3848–60.

Narikazu Iijima, Miyamura K, Itou T, Tanimoto M, Sobue R,

Saito H, et al, Functional Expression of Fas (CD95) in Acute

Myeloid Leukemia Cells in the Context of CD34 and CD38

Expression: Possible Correlation With Sensitivity to

Chemotherapy Blood 1997:90(12):pp. 4901–9.

Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke

RC. A role for CD95 ligand in preventing graft rejection. Nature

;377:630–2.

Buik RN, Till JE, McCulloch EA. Colony assay for proliferation

blast cells circulating in myeloblastic leukemia. Lancet

;1(8016):862–3.

Di Pietro R, Secchiero P, Rana R, Gibellini D, Visani G, Bemis

K, et al. Ionizing radiation sensitizes erythroleukemic cells but

not normal erythroblasts to tumor necrosis factor-related

apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by

selective up-regulation of TRAIL-R1. Blood 2001;97:2596–603.

Dirks W, Schone S, Uphoff C, Quentmeier H, Pradella S, Drexler

HG. Expression and function of CD95 (FAS/APO-1) in leukaemialymphoma tumour lines. Br J Haematol 1997;96:584–93.

Dong J, Naito M, Mashima T, Jang WH, Tsuruo T. Genetically

recessive mutant of human monocytic leukemia U937 resistant to

tumor necrosis factor-alpha-induced apoptosis. J Cell Physiol

;174:179–85.

J Ayub Med Coll Abbottabad 2012;24(1)

http://www.ayubmed.edu.pk/JAMC/24-1/Faris.pdf 115

Shiiki K, Yoshikawa H, Kinoshita H, Takeda M, Ueno A,

Nakajima Y, et al. Potential mechanisms of resistance to

TRAIL/Apo2 L-induced apoptosis in human promyelocytic

leukemia HL-60 cells during granulocytic differentiation. Cell

Death Differ 2000;7(10):939–46.

Tourneur L, Delluc S, Lévy V, Valensi F, Radford-Weiss I,

Legrand O, et al. Absence or Low Expression of Fas-Associated

Protein with Death Domain in Acute Myeloid Leukemia Cells

Predicts Resistance to Chemotherapy and Poor Outcome. Cancer

Res 2004;64:8101–8.

Hitoshi Y, Lorens J, Kitada SI, Fisher J, LaBarge M, Ring HZ, et

al. Toso, a cell surface, specific regulator of Fas-induced

apoptosis in T cells. Immunity 1998;8(4):461–71.

ElTounsi E, Alenzi FQ. TOSO, an alternative resistance

mechanism to Fas induction of apoptosis in AML. Egypt J

Hematol 2007;32(3):213–28.

Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in

cancer: patent review. Expert Opin Ther Pat 2010;20:1723–37.

Nakagawa Y, Hasegawa M, Kurata M, Yamamoto K, Abe S,

Inoue M, et al. Expression of IAP-family proteins in adult acute

mixed lineage leukemia (AMLL). Am J Hematol

;78(3):173–80.

ElTounsi E, Alenzi FQ. Increased expression of survivin in TNFrelated apoptosis inducing ligand (TRAIL) resistant AML. Egypt

J Hematol 2007;32(3):147–58.

Altieri DC, Marchisio PC. Survivin apoptosis: an interloper

between cell death and cell proliferation in cancer. Lab Invest

;79(11):1327–33. Erratum in Lab Invest 1999;79(12):1543.

Invernizzi R, Travaglino E, Benatti C, Malcovati L, Della Porta

M, Cazzola M, et al. Survivin expression, apoptosis and

proliferation in chronic myelomonocytic leukemia. Eur J

Haematol 2006;76:494–501.

Wagner M, Schmelz K, Wuchter C, Ludwig WD, Dörken B,

Tamm I. In vivo expression of survivin and its splice variant

surviving 2B: impact on clinical outcome in acute myeloid

leukemia. Int J Cancer 2006;119(6):1291–7.

Eltounsi I, Andreeff M. Deferential biological and biochemical

effects of TNF- related apoptosis inducing ligand on leukemic

and normal CD34+ hematopoietic cells. EJH 2002;28(1):

Shinohara H, Yagita H, Ikawa Y, Oyaizu N. Fas drives cell cycle

progression in glioma cells via extracellular signal transduction

kinase activation. Cancer Res 2000;60:1766–71.

Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR, et al.

The alkylphospholipid perifosine induces apoptosis of human

lung cancer cells requiring inhibition of Akt and activation of the

extrinsic apoptotic pathway. Mol Cancer Ther 2007;6:2029–38.

Oto OA, Paydas S, Tanriverdi K, Seydaoglu G, Yavuz S, Disel

U. Survivin and EPR-1 expression in acute leukemias: Prognostic

significance and review of the literature. Leuk Res

;31:1495–501.

Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting

death-inducing receptors in cancer therapy. Oncogene

;26:3745–57.

Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokineregulated expression of survivin in myeloid leukemia. Blood

;97:2784–90.

Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu

X. ASPP1 and ASPP2: common activators of p53 family

members. Mol Cell Biol 2004;24:1341–50.

Zhao J, Wu G, Bu F, Lu B, Liang A, Cao L, et al. Epigenetic

silence of ankyrin-repeat–containing, SH3-domain-containing,

and proline-rich-region-containing Protein 1 (ASPP-1) and

ASPP-2 genes promotes tumor growth in hepatitis B viruspositive hepatocellular carcinoma. Hepatol 2010;51:142–53.

Trigiante G, Lu X. ASPP and cancer. Nat Rev Cancer

;6:217–26.

Sullivan A, Lu X. ASPP: A new family of oncogenes and tumor

suppressor genes. Br J Cancer 2007;96:196–200.

Alenzi FQ. Cell type specific expression of the apoptosis

stimulating protein (ASPP-2) in human tissues. Acta Microbiol

Immunol Hung 2010;57:419–29.

Kampa KM, Bonin M, Lopez CD. New insights into the

expanding complexity of the tumor suppressor ASPP2. Cell

Cycle 2009;8:2871–6.

Downloads

Published

2012-03-01

Most read articles by the same author(s)